AMPIO PHARMACEUTICALS, INC.: 10-Q filed 2019-08-09
What AMPIO PHARMACEUTICALS, INC. reported in its quarterly report filed 2019-08-09 (fiscal Q2 2019): 30 published measures, 87 facts as tagged in accession 0001558370-19-007896.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2019-08-09
- Fiscal period
- fiscal Q2 2019
- Accession
- 0001558370-19-007896 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All AMPIO PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | 20,888,676 | USD | |
| At 2018-12-31 | 14,030,110 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | 9,778,223 | USD | |
| At 2018-12-31 | 8,794,014 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | 11,110,453 | USD | |
| At 2019-03-31 | -467,983 | USD | |
| At 2018-12-31 | 5,236,096 | USD | |
| At 2018-06-30 | -3,768,672 | USD | |
| At 2018-03-31 | -8,856,812 | USD | |
| At 2017-12-31 | -34,176,885 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | 12,782,758 | USD | |
| At 2018-12-31 | 7,585,392 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-06-30 | 420,766 | USD | 91 |
| 2019-01-01 to 2019-06-30 | -5,390,868 | USD | 181 |
| 2018-04-01 to 2018-06-30 | 4,620,201 | USD | 91 |
| 2018-01-01 to 2018-06-30 | 26,659,673 | USD | 181 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-06-30 | -5,893,914 | USD | 181 |
| 2018-01-01 to 2018-06-30 | -6,602,315 | USD | 181 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-06-30 | 13,590 | USD | 181 |
| 2018-01-01 to 2018-06-30 | 442,132 | USD | 181 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-06-30 | 11,104,870 | USD | 181 |
| 2018-01-01 to 2018-06-30 | 3,496,305 | USD | 181 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-06-30 | -13,590 | USD | 181 |
| 2018-01-01 to 2018-06-30 | -442,132 | USD | 181 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | -176,393,376 | USD | |
| At 2018-12-31 | -171,002,508 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-06-30 | 115,031,289 | shares | 91 |
| 2019-01-01 to 2019-06-30 | 113,078,639 | shares | 181 |
| 2018-04-01 to 2018-06-30 | 86,300,054 | shares | 91 |
| 2018-01-01 to 2018-06-30 | 84,630,970 | shares | 181 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-06-30 | 118,770,096 | shares | 91 |
| 2019-01-01 to 2019-06-30 | 117,349,516 | shares | 181 |
| 2018-04-01 to 2018-06-30 | 92,999,810 | shares | 91 |
| 2018-01-01 to 2018-06-30 | 91,534,677 | shares | 181 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-06-30 | 0 | USD/shares | 91 |
| 2019-01-01 to 2019-06-30 | -0.05 | USD/shares | 181 |
| 2018-04-01 to 2018-06-30 | 0.05 | USD/shares | 91 |
| 2018-01-01 to 2018-06-30 | 0.32 | USD/shares | 181 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-06-30 | -0.03 | USD/shares | 91 |
| 2019-01-01 to 2019-06-30 | -0.05 | USD/shares | 181 |
| 2018-04-01 to 2018-06-30 | -0.03 | USD/shares | 91 |
| 2018-01-01 to 2018-06-30 | -0.07 | USD/shares | 181 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | 5,355,788 | USD | |
| At 2018-12-31 | 5,997,582 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-06-30 | 100,354 | USD | 181 |
| 2018-01-01 to 2018-06-30 | 192,235 | USD | 181 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | 14,412,023 | USD | |
| At 2018-12-31 | 7,998,672 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | 2,324,087 | USD | |
| At 2018-12-31 | 1,384,230 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-06-30 | 3,581,488 | USD | 91 |
| 2019-01-01 to 2019-06-30 | 6,257,355 | USD | 181 |
| 2018-04-01 to 2018-06-30 | 3,131,637 | USD | 91 |
| 2018-01-01 to 2018-06-30 | 6,706,470 | USD | 181 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-06-30 | 2,136,834 | USD | 91 |
| 2019-01-01 to 2019-06-30 | 3,701,012 | USD | 181 |
| 2018-04-01 to 2018-06-30 | 2,114,783 | USD | 91 |
| 2018-01-01 to 2018-06-30 | 4,159,259 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | 142,207,862 | shares | |
| At 2018-12-31 | 110,941,516 | shares |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | 1,087,009 | USD | |
| At 2018-12-31 | 0 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | 1,589,000 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | 5,448,000 | USD | |
| At 2018-12-31 | 4,793,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-06-30 | 1,629,265 | USD | |
| At 2018-12-31 | 413,280 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-06-30 | 420,766 | USD | 91 |
| 2019-01-01 to 2019-06-30 | -5,390,868 | USD | 181 |
| 2019-01-01 to 2019-03-31 | -5,811,634 | USD | 90 |
| 2018-04-01 to 2018-06-30 | 4,620,201 | USD | 91 |
| 2018-01-01 to 2018-06-30 | 26,659,673 | USD | 181 |
| 2018-01-01 to 2018-03-31 | 22,039,472 | USD | 90 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-06-30 | -3,560,403 | USD | 91 |
| 2019-01-01 to 2019-06-30 | -6,212,505 | USD | 181 |
| 2018-04-01 to 2018-06-30 | -3,131,637 | USD | 91 |
| 2018-01-01 to 2018-06-30 | -6,706,470 | USD | 181 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-06-30 | 1,444,654 | USD | 91 |
| 2019-01-01 to 2019-06-30 | 2,556,343 | USD | 181 |
| 2018-04-01 to 2018-06-30 | 1,016,854 | USD | 91 |
| 2018-01-01 to 2018-06-30 | 2,547,211 | USD | 181 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-01-01 to 2019-06-30 | 736,196 | USD | 181 |
| 2018-01-01 to 2018-06-30 | 621,204 | USD | 181 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2019-04-01 to 2019-06-30 | 4,002,254 | USD | 91 |
| 2019-01-01 to 2019-06-30 | 866,487 | USD | 181 |
| 2018-04-01 to 2018-06-30 | 7,751,838 | USD | 91 |
| 2018-01-01 to 2018-06-30 | 33,366,143 | USD | 181 |
Inspect the source
- Entity
- AMPIO PHARMACEUTICALS, INC. / CIK 0001411906
- Captured
- SEC response SHA-256
661bdc81760eff21f73144c4212b3daf37fe49f00b5469e6e153f0c2138a63e3
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001411906.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))